Literature DB >> 3526153

Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls.

E Adelroth, M M Morris, F E Hargreave, P M O'Byrne.   

Abstract

Leukotrienes C4 and D4 may serve as chemical mediators in asthma. Although patients with asthma are known to be hyperresponsive to the bronchoconstrictive effects of histamine and methacholine, whether the same is true for the leukotrienes is controversial. We compared the airway responses to methacholine and to leukotrienes C4 and D4 in 12 asthmatic patients and 6 controls. We found that the patients were more responsive to the leukotrienes than the controls, and we observed a linear correlation between airway response to methacholine and that to leukotriene C4 (r = 0.68, P less than 0.01) and D4 (r = 0.79, P less than 0.001). However, relative to the airway response to methacholine, the response to the leukotrienes was much greater in the controls than in the patients. Furthermore, the asthmatic subjects who were most responsive to methacholine had the lowest relative airway response to both leukotrienes. Thus, the patients with the greatest airway responsiveness to methacholine paradoxically showed the lowest relative airway response to the leukotrienes. In contrast, this difference in relative airway responses has not been observed between methacholine and other bronchoconstrictor mediators, such as histamine. Although no adequate explanation for these observations has yet emerged, our data suggest that leukotrienes C4 and D4 are unique bronchoconstrictors with a possible role in the pathogenesis of asthma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526153     DOI: 10.1056/NEJM198608213150803

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  27 in total

Review 1.  Antileukotrienes and laboratory models of asthma.

Authors:  S C Lazarus
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 3.  Asthma--the changing face of drug therapy.

Authors:  J Legg; J Warner
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

Review 4.  Exercise-induced bronchospasm in the elite athlete.

Authors:  Kenneth W Rundell; David M Jenkinson
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

Review 5.  The pharmacology of airway hyperresponsiveness and inflammation.

Authors:  R Pauwels
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 6.  Management of anaphylactic and anaphylactoid reactions during anesthesia.

Authors:  B Eon; L Papazian; F Gouin
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

7.  Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005.

Authors:  A L Hamilton; R M Watson; G Wyile; P M O'Byrne
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

8.  Effect of zileuton on theophylline pharmacokinetics.

Authors:  G R Granneman; R A Braeckman; C S Locke; J H Cavanaugh; L M Dubé; W M Awni
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

9.  Allergic lung responses are increased in prostaglandin H synthase-deficient mice.

Authors:  S H Gavett; S L Madison; P C Chulada; P E Scarborough; W Qu; J E Boyle; H F Tiano; C A Lee; R Langenbach; V L Roggli; D C Zeldin
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

10.  Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma.

Authors:  R I Ketchell; M D'Amato; M W Jensen; B J O'Connor
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.